GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (STU:HG6) » Definitions » 10-Year ROIIC %

Mayne Pharma Group (STU:HG6) 10-Year ROIIC % : -27.26% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Mayne Pharma Group 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Mayne Pharma Group's 10-Year ROIIC % for the quarter that ended in Jun. 2024 was -27.26%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Mayne Pharma Group's 10-Year ROIIC % or its related term are showing as below:

STU:HG6's 10-Year ROIIC % is ranked worse than
82.19% of 932 companies
in the Drug Manufacturers industry
Industry Median: 3.685 vs STU:HG6: -27.26

Mayne Pharma Group 10-Year ROIIC % Historical Data

The historical data trend for Mayne Pharma Group's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group 10-Year ROIIC % Chart

Mayne Pharma Group Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.22 -0.03 -9.04 -38.15 -27.26

Mayne Pharma Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.04 - -38.15 - -27.26

Competitive Comparison of Mayne Pharma Group's 10-Year ROIIC %

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's 10-Year ROIIC % falls into.



Mayne Pharma Group 10-Year ROIIC % Calculation

Mayne Pharma Group's 10-Year ROIIC % for the quarter that ended in Jun. 2024 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -76.2338256 (Jun. 2024) - 12.3741028 (Jun. 2014) )/( 463.868 (Jun. 2024) - 160.403 (Jun. 2014) )
=-88.6079284/303.465
=-29.20%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Mayne Pharma Group  (STU:HG6) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Mayne Pharma Group 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Mayne Pharma Group Headlines

No Headlines